FDA 483 - Mark Adaimy MD - November 16, 2020

An FDA inspection of Mark J. Adalmy, MD, Clinical Investigator in Las Vegas, NV, revealed significant non-compliance with clinical investigation protocols. The firm failed to properly report serious adverse events, administered incorrect or expired doses, and neglected required laboratory safety assessments for study subjects. These findings indicate a serious lack of adherence to regulatory requirements and study protocols.